Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Westlake Therapeutics

Request full access

Developing a variety of innovative cell therapy products for rare diseases

Hangzhou, ChinaFounded 2019Biotech & Life Sciences

About Westlake Therapeutics

Westlake Therapeutics (Hangzhou) Co., Ltd. is a biotechnology firm established in June 2020, operating from Hangzhou, China. It was the first spin-off company from Westlake University and was founded by Dr. Xiaofei Gao. Dr. Gao earned his Ph.D. from the University of Kansas and conducted postdoctoral research at the Massachusetts Institute of Technology before joining Westlake University in 2017 to focus on cellular drug development. His work led to the creation of the REDx therapeutic platform, a core technology for the company.

The company centers its operations on developing therapies based on engineered Red Blood Cells (RBC). This approach is applied to a wide range of human diseases, including cancers, as well as immunological and metabolic disorders. The business model revolves around the research, development, and eventual commercialization of these cell therapies. Westlake Therapeutics establishes collaborations with hospitals, medical research institutes, and other biotech companies to advance its clinical research. The company has secured significant venture capital, having raised nearly 300 million RMB to fund its R&D, team expansion, and infrastructure development.

Westlake Therapeutics' core product is its proprietary REDx platform, which engineers RBCs to function as therapeutic agents. This technology involves modifying either stem cell-derived or natural RBCs to carry various drug modalities. The process includes isolating erythrocytes, attaching drugs to them using linkers, and creating an Erythrocyte-drug-Conjugate (EDC). These engineered cells are then cultivated ex vivo in large numbers before being reintroduced into patients. A key benefit of this platform is its potential to create off-the-shelf cellular products at a lower cost. The company's pipeline features several first-in-class candidates for personalized transfusions and treatments. One of its lead products, WTX-212, an Erythrocyte-αPD-1 antibody conjugate, is in clinical trials for cancer patients who have not responded to conventional immunotherapy and has shown promising results.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
54.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2026 $28M $110M Efung Capital · Real Power Capital · HongShan · Suzhou International Development Venture Capital Holding ↗
LATE VCOther financing Jul 2021 $14M $55M Sequoia · Fang Group · CD Capital —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Westlake Therapeutics website traffic

Latest recorded traffic for Westlake Therapeutics is 900 monthly website visits, up 462.5% over the last three months.

Latest monthly visits900 3-month web change+462.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Westlake Therapeutics in the Hangzhou ecosystem

Live from Dealroom

The Westlake Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Tasly Pharmaceutical
  • Westlake Fund
  • Sequoia
  • CD Capital
  • Real Power Capital
  • Suzhou International Development Venture Capital Holding
  • Efung Capital
  • HongShan

Series B and later1 investor entered at this stage

  • Fang Group

Other known investors2 additional known investors

  • University of Chinese Academy of Sciences
  • Westlake University
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Hangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Westlake Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Westlake Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.